Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants

European Journal of Clinical Chemistry and Clinical Biochemistry

Volumn 34, Issue 8, 1996, Pages 599-608

  Aviram, Michael ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN E; ARACHIDONATE 15 LIPOXYGENASE; BEZAFIBRATE; CAPTOPRIL; CHOLESTEROL; COLESTYRAMINE; ENALAPRIL; FLUINDOSTATIN; FOSINOPRIL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXYGENASE; PHOSPHOLIPID; POLYPHENOL; PRAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELENIUM; SIMVASTATIN;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; DIET SUPPLEMENTATION; FOAM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTENSION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIOXIDANTS; ARTERIOSCLEROSIS; CHOLESTEROL; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MICE;

EID: 0029837209     PISSN: 09394974     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-9.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-24.
3. Avirarn M. Effect of lipoproteins and platelets on macrophage cholesterol metabolism. In: Harris JR, editor. Blood cell biochemistry. Megakaryocytes, platelets, macrophages and eosinophils (volume 2). New York: Plenum Publishing Co NY 1991 ; 179-208.
4. Aviram M. LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Thromb Haemost 1995; 74 (l):560-4.
5. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vase Biol 1995; 15:551-61.
6. Crawford DW, Blankenhorn DH. Arterial wall oxygénation, oxyradicals, and atherosclerosis. Atherosclerosis 1991; 89:97-108.
7. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344:793-5.
8. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785-92.
9. Halliwell B. Oxidation of low-density lipoproteins: questions of initiation, propagation, and the effect of antioxidants. Am J ClinNutr 1995; 61:670S-7S.
10. Jürgens G, Hoff HF, Chisolm GM, Esterbauer H. Modification of human serum low density lipoprotein by oxidation-characterization and pathophysiological implications. Chem Phys Lipids 1987; 45:315-36.
11. Penn MS, Chisolm GM. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 1994; 108:821 S9.
12. Aviram M. Beyond cholesterol: modifications of lipoproteins and increased atherogenicity. In: Neri Serneri GG, Gensini GF, Abbate R, Frisco D, editors. Atherosclerosis, inflammation and thrombosis. Florence: Scientific Press-Florence, Italy, 1993:15-36.
13. Aviram M. Macrophage-mediated oxidation of LDL and atherosclerosis. In: Bellomo G, Finardi G, Maggi E, Rice-Evans C, editors. Free radicals, lipoprotein oxidation and atherosclerosis: biological and clinical aspects. London, UK: Richelieu Press, 1995;I01-37.
14. Aviram M. Oxidative modification of low density lipoprotein and atherosclerosis. Isr J Med Sei 1995; 31:241-9.
15. Steinbrecher UP, Zhang H, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Rad Biol Med 1990; 9:155-68.
16. Smith LL, Johnson BH. Biological activities of oxysterols. Free Rad Biol Med 1989; 7:285-332.
17. Panasenko OM, Vol'nove TV, Azizova OA, Vladimirov YA. Free radical modification of lipoproteins and cholesterol accu-mulation in cells upon atherosclerosis. Free Rad Biol Med 1991; 10:137-48.
18. Suits AG, Chait A, Aviram M, Heinecke JW. Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor dependent foam cell formation. Proc Natl Acad Sei USA 1989; 86:2713-7.
19. Heinecke JW, Suits AG, Aviram M, Chait A. Phagocytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events. Arterioscler Thromb 1991; 11:1643 -51.
20. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms oxidation, inflammation and genetics. Circulation 1995; 91:248896.
21. Regnstrom J, Nilsson J. Lipid oxidation and inflammation-induced intimai fibrosis in coronary heart disease. J Lab Clin Med 1994; 124:162-8.
22. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993; 98:1-9.
23. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage. Annu Rev Biochem 1983; 52:223-61.
24. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol. Science 1986; 232:34-9.
25. Aviram M, Lund-Katz S, Phillips M, Chait A. The influence of the triglycéride content of low density lipoprotein on the interaction of apolipoprotein B-100 with cells. J Biol Chem 1988; 263:16842-8.
26. Aviram M, Bierman EL, Chait A. Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem 1988; 263:15416-22.
27. Aviram M, Keidar S, Rosenblat M, Brook JG. Reduced uptake of cholesterol esterase-modified low density lipoprotein by macrophages. J Biol Chem 1991; 266:11567-74.
28. Aviram M, Maor I. Phospholipase D modified low density lipoprotein is taken up by macrophages at increased rate: a possible role for phosphatidic acid. J Clin Invest 1993; 91:1942-52.
29. Aviram M, Maor I. Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages. Biochem Biophys Res Commun 1992; 185:465-72.
30. Lavy A, Dankner G, Aviram M. Galactosidase-modified LDLdemonstrates increased susceptibility to undergo lipid peroxidation and enhanced uptake by macrophages. Isr J Med Sei 1994; 30:905-7.
31. Aviram M. Low density lipoprotein modification by cholesterol oxidase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem 1992; 267:218-25.
32. Aviram M. Platelet-modified low-density lipoprotein: studies in normals and in patients with homozygous familial hypercholesterolemia. Clin Biochem 1987; 29:91-5.
33. Aviram M, Furhman B, Kiedar S, Maor I, Rosenblat M, Dankner G, Brook JG. Platelet-modified low density lipoprotein induces macrophage cholesterol accumulation and platelet activation. J Clin Chem Clin Biochem 1989; 27:3-12.
34. Keidar S, Kaplan M, Aviram M. Angiotensin II modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb 1996; 16:97-105.
35. Kruth HS. Localization of unesterified cholesterol in human atherosclerosis lesions: demonstration of filipin-positive, oil red O-negative particles. Am J Pathol 1984; 114:201-7.
36. Sparrow CP, Parthasarathy S, Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem 1989; 264:2599-604.
37. Arai H, Kita T, Yokode M, Narumiya S, Kawai C. Multiple receptors for modified low density lipoprotein in mouse peritoneal macrophage: different uptake mechanisms for acetylated and oxidized low density lipoproteins. Biochem Biophys Res Commun 1989; 159:1375-82.
38. Aviram M. The contribution of the macrophage receptor for oxidized LDL to its cellular uptake. Biochem Biophys Res Commun 1991; 179:359-65.
39. Keidar S, Brook JB, Rosenblat M, Fuhrman B, Dankner G, Aviram M. Involvement of the macrophage LDL receptor binding domains in the uptake of oxidized LDL. Arterioscler Thromb 1992; 12 (4):484-93.
40. Keidar S, Kaplan M, Rosenblat M, Brook JB, Aviram M. Apolipoprotein E and lipoprotein lipase reduce macrophage degradation of oxidized VLDL but increase cellular degradation of native VLDL. Metabolism 1992; 41 (ll):1185-92.
41. Williams KJ, Fless FM, Pétrie KA, Sanyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. J Biol Chem 1992; 267:13284-92.
42. Maor I, Aviram M. Oxidized low density lipoprotein leads to macrophage accumulation of unesterified cholesterol as a result of lysosomal trapping of the lipoprotein hydrolyzed cholesteryl ester. J Lipid Res 1994; 35:803-19.
43. Roma P, Catapano AL, Bertulli BS, Varesi R, Fumaglli, Bernini F. Oxidized LDL increases free cholesterol and fail to stimulate cholesterol esterification in murine macrophages. Biochem Biophys Res Commun 1990; 171:123-31.
44. Jialal I, Chait A. Differences in the metabolism of oxidatively modified low density lipoprotein and acetylated low density lipoprotein by human endothelial cells: inhibition of cholesterol esterification by oxidatively modified low density lipoprotein. J Lipid Res 1989; 30:1561-8.
45. Zhang H, Basra HJK, Steinbrecher UP. Effects of oxidatively modified LDL on cholesterol esterification in cultured macrophages. J Lipid Res 1990; 31:1361-9.
46. Aviram M, Bar M, Maor I. Macrophage localization of unesterified cholesterol affect cellular cholesterol regulation and its cytotoxicity: atherogenicity of excess plasma membrane cholesterol. Bull Mol Biol Med 1995; 20:49-54.
47. Maor I, Mandel H, Aviram M. Macrophage uptake of oxidized low density lipoprotein inhibits lysosomal sphingomyelinase, thus causing the accumulation of unesterified cholesterolsphingomyelin rich particles in the lysosomes: a possible role for 7-ketocholesterol. Arterioscler Thromb 1995; 15:1378-87.
48. Parthasarathy S, Steinberg D. Cell-induced oxidation of LDL. Curr Opin Lipidol 1992; 3:313-7.
49. Parthasarathy S, Santanam N. Mechanisms of oxidation, antioxidants, and atherosclerosis. Curr Opin Lipidol 1994; 5:371-5.
50. Stocker R. Lipoprotein oxidation: mechanistic aspects, methological approaches and clinical relevance. Curr Opin Lipidol 1994; 5:422-33.
51. Mitchinson MJ, Ball RY, Carpenter KLH, Enright JH. Macrophages and ceroid in human atherosclerosis. Eur Heart J 1990; E Suppl 11:116-21.
52. Aviram M, Rosenblat M. Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor. J Lipid Res 1994; 35:385-98.
53. Heinecke JW, Baker L, Roasen H, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest 1986; 77:757-61.
54. Yla-Hertuuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, Steinberg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sei USA 1990; 87:6959-63.
55. Cathcart MK, McNally AK, Morel DW, Chisolm GM. Superoxide anion participation in human monocyte mediated-oxidation of low density lipoprotein and conversion of low density lipoprotein to a cytotoxin. J Immunol 1989; 142:1963-72.
56. Rosenblat M, Aviram M. Activation of NADPH oxidase but not of 15-lipoxygenase by low density lipoprotein (LDL) is required for LDL oxidation by macrophages. Metabolism 1996; 45 (9):1-12.
57. Fuhrman B, Oiknine J, Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL and affects their secretory properties. Atherosclerosis 1994; 111:65-78.
58. Keidar S, Kaplan M, Hoffman A, Brook JG, Aviram M. Angiotensin II stimulates macrophage-mediated lipid peroxidation of low density lipoprotein. Atherosclerosis 1995; 115:201-15.
59. Carter D, Fuhrman B, Aviram M. Macrophage activation wit phorbol myristate acetate is associated with cellular lipid pei oxidation. Isr J Med Sei 1996; 32:479-485.
60. Keidar S, Brook JG, Aviram M. Angiotensin II enhances lipi peroxidation of low density lipoprotein. N Physiol Sei 199; 8:245-8.
61. Yla-Herttula S, Palinski W, Rosenfeld ME, Steinberg D, Wit2 turn JL. Lipoproteins in normal and atherosclerotic aorta. Ei Heart J 1990; R Suppl 11:88.
62. Haberland ME, Fogelman AM. The role of altered lipoprotein in the pathogenesis of atherosclerosis. Am Heart J 198"/ 113:573-7.
63. Chait A. Progression of atherosclerosis: the cellular biology Eur Heart J 1987; E Suppl i:15-22.
64. Aviram M, Maor 1, Keidar S, Hayek T, Oiknine J, Bar-El Adler Z, et al. Lesioned low density lipoprotein in atherisclero tic apolipoprotein E-deficient transgenic mice and in human is oxidized and aggregated. Biochem Biophys Res Commu: 1995; 16:501-13.
65. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Ahlstron C, Fager G, Bondjers G. Effect of arterial proteoglycans am glycosaminoglycans on LDL oxidation and its uptake by hu man macrophages and arterial smooth muscular cells. Arterio scler Thromb 1992; 12:569-79.
66. Lavy A, Brook JG, Dankner G, Ben Amotz A, Aviram M Enhanced in vitro oxidation of plasma lipoproteins dérivée from hypercholesterolemic patients. Metabolism 1991 40:794-9.
67. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasm; lipoprotein lipid peroxidation in apo E-deficient mice. Bio chem Biophys Res Commun 1994; 201:1567-74.
68. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lo vastatin inhibits LDL oxidation and alters its fluidity and up take by macrophages: in vitro and in vivo studies. Metabolisir 1992; 41 (3):229-35.
69. Hoffman R, Brook JG, Aviram M. Hypolipidemic therapy reduces lipoprotein susceptibility to undergo lipid peroxidation in vitro and ex vivo studies. Atherosclerosis 1992; 93:105-13
70. Keidar S, Brook JG, Aviram M. Pravastatin inhibits cellulai cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages. Br J Clin Pharmacol 1994 38:513-9.
71. Keidar S, Kaplan M, Shapira H, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensir II. Atherosclerosis 1994; 104:71-84.
72. Nishigaki I, Hagihara M, Tsunekana H, Maseki M, Yagi K Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med 1981; 25:373-8.
73. Maggi E, Bellazzi R, Gazo A, Secciam T, Bellomo G. Autoantibodies against oxidatively-modified LDL in chronic patients undergoing dialysis. Kidney Intern 1994; 46:869-76.
74. Bergman R, Kasif Y, Aviram M, Maor 1, Ullman Y, Gdal-on M, Friedman-Birnbaum R. Normolipidemic xanthelasma palpebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Dermato-Venerol 1996; 76:107-10.
75. Aviram M, Keidar S, Brook JB. Dual effect of lovastatin and simvastatin on LDL-macrophage interaction. Eur J Clin Chem Clin Biochem 1991; 29:657-64.
76. Aviram M. Antioxidant-mediated inhibition of macrophage modification of low density lipoprotein. Life Chem Reports 1994; 12:69-78.
77. Stocker R, Frei B. Endogenous antioxidant defenses in human blood plasma. In: Frei B, editor. Oxidative stress, oxidants and antioxidants. New York: Academic Press, 1991:213-43.
78. Aviram M, Käsern E. Dietary olive oil reduces the susceptibility of low density lipoprotein to lipid peroxidation and inhibits lipoprotein uptake by macrophages. Ann Nutr Metabol 1993; 91:1942-52.
79. Lavy A, Ben Amotz A, Aviram M. Preferential inhibition of LDL oxidation by the all-trans isomer of -carotene in comparison to the 9-cis -carotene. Eur J Clin Chem Clin Biochem 1993; 31:83-90.
80. Levy Y, Ben-Amoth A, Aviram M. Effect of dietary supplementation of -carotene to humans on its binding to plasma LDL and on the lipoprotein susceptibility to undergo oxidative modification: comparison of the synthetic all Irans isomer with the natural algae -carotene. J Nutr Environ Med 1995; 5:13-22.
81. Levy Y, Kaplan M. -Carotene on human monocyte-macrophage-mediated oxidation of low density lipoprotein. Isr J Med Sei 1996; 32:473-8.
82. Fuhrman B, Lavy A, Aviram M. Dietary supplementation of red wine reduces the susceptibility of human plasma and LDL to undergo lipid peroxidation. Am J Clin Nutr 1995; 61:549-54.
83. Fuhrman B, Aviram M. White wine reduces LDL susceptibility to oxidation in vitro but not in vivo. Am J Clin Nutr 1996; 63:403-4.
84. Furhman B, Buch S, Aviram M. Licorice ethanolic extract protects LDL against lipid peroxidation: in vitro and in vivo studies. Arterioscler Thromb 1996; In press.
85. Via Y, Belinki P, Aviram M. Antioxidative capacity of isolated licorice constituents. Arch Biochem Biophys 1996; In press.
86. Hennekens CH, Buring JE, Nanson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145-9.
87. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen M, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-5.
88. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. Br Med J 1996; 312:478-81.
89. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet 1993; 342:100711.
90. Hertog MG, Kromohout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 1995; 155:381-6.
91. Rapola JM, Virtamo J, Haukka JK, Heinonen OP, Albanes O, Taylor PR, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. J Am Med Ass 1996; 275:69398.
92. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-35.
93. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-6.
94. Hayek T, Oiknine J, Dankner G, Brook GJ, Aviram M. HDL apolipoprotein A-I attenuate oxidative modification of low density lipoprotein. Eur J Clin Chem Clin Biochem 1995; 33:721-5.
95. Aviram M. LDL oxidation by macrophages contributes to foam cell formation. Acta Angiol 1995; 1 (2): 103-10.